

US Patent & Trademark Office

Patent Public Search | Text View

United States Patent	12384827
Kind Code	B2
Date of Patent	August 12, 2025
Inventor(s)	Zhang; Tong et al.

Chimeric NK receptor and methods for treating cancer

Abstract

The present invention relates to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif. Methods for using the chimeric receptors are further provided.

Inventors: Zhang; Tong (Beijing, CN), Sentman; Charles L. (West Lebanon, NH)

Applicant: THE TRUSTEES OF DARTMOUTH COLLEGE (Hanover, NH)

Family ID: 1000008750840

Assignee: THE TRUSTEES OF DARTMOUTH COLLEGE (Hanover, NH)

Appl. No.: 17/748683

Filed: May 19, 2022

Prior Publication Data

Document Identifier	Publication Date
US 20220348627 A1	Nov. 03, 2022

Related U.S. Application Data

continuation parent-doc US 12407440 20090319 ABANDONED child-doc US 14600799
continuation-in-part parent-doc US 11575878 US 7994298 20110809 WO PCT/US2005/031100
20050831 child-doc US 12407440
division parent-doc US 16458740 20190701 US 11339199 child-doc US 17748683
division parent-doc US 14600799 20150120 US 10336804 20190702 child-doc US 16458740
us-provisional-application US 60681782 20050517
us-provisional-application US 60612836 20040924

Publication Classification

Int. Cl.: **C07K14/705** (20060101); **A61K38/10** (20060101); **A61K40/11** (20250101); **A61K40/42** (20250101); **A61K45/06** (20060101); **C07K14/715** (20060101)

U.S. Cl.:

CPC **C07K14/705** (20130101); **A61K38/10** (20130101); **A61K40/11** (20250101); **A61K40/4224** (20250101); **A61K45/06** (20130101); **C07K14/715** (20130101); **A61K2239/31** (20230501); **A61K2239/38** (20230501); **A61K2239/48** (20230501)

Field of Classification Search

CPC: C07K (14/705)

References Cited

U.S. PATENT DOCUMENTS

Patent No.	Issued Date	Patentee Name	U.S. Cl.	CPC
5359046	12/1993	Capon et al.	N/A	N/A
5415874	12/1994	Bender et al.	N/A	N/A
5552300	12/1995	Makrides et al.	N/A	N/A
5667967	12/1996	Steinman et al.	N/A	N/A
5686281	12/1996	Roberts	N/A	N/A
5830755	12/1997	Nishimura et al.	N/A	N/A
5851828	12/1997	Seed et al.	N/A	N/A
6103521	12/1999	Capon et al.	N/A	N/A
6284240	12/2000	Seed et al.	N/A	N/A
6407221	12/2001	Capon et al.	N/A	N/A
6407319	12/2001	Rose-Fricker et al.	N/A	N/A
6410319	12/2001	Raubitschek et al.	N/A	N/A
6464978	12/2001	Brostoff et al.	N/A	N/A
6753162	12/2003	Seed et al.	N/A	N/A
6770749	12/2003	Ellenhorn et al.	N/A	N/A
6984382	12/2005	Groner et al.	N/A	N/A
7049136	12/2005	Seed et al.	N/A	N/A
7052906	12/2005	Lawson et al.	N/A	N/A
7070995	12/2005	Jensen	N/A	N/A
7094599	12/2005	Seed et al.	N/A	N/A
7446179	12/2007	Jensen et al.	N/A	N/A
7446190	12/2007	Sadelain et al.	N/A	N/A
7456263	12/2007	Sherman et al.	N/A	N/A
7514537	12/2008	Jensen	N/A	N/A
7569357	12/2008	Kranz et al.	N/A	N/A
7608410	12/2008	Dunn et al.	N/A	N/A
7618817	12/2008	Campbell	N/A	N/A
7655461	12/2009	Finn et al.	N/A	N/A
7763243	12/2009	Lum et al.	N/A	N/A
7820174	12/2009	Wang et al.	N/A	N/A

7994298	12/2010	Zhang et al.	N/A	N/A
8252914	12/2011	Zhang et al.	N/A	N/A
8283446	12/2011	Jakobsen et al.	N/A	N/A
8465743	12/2012	Rosenberg et al.	N/A	N/A
8519100	12/2012	Jakobsen et al.	N/A	N/A
8956828	12/2014	Bonini et al.	N/A	N/A
2001/0007152	12/2000	Sherman et al.	N/A	N/A
2002/0045241	12/2001	Schendel	N/A	N/A
2002/0102691	12/2001	David et al.	N/A	N/A
2002/0137697	12/2001	Eshhar et al.	N/A	N/A
2003/0060444	12/2002	Finney et al.	N/A	N/A
2003/0077249	12/2002	Bebbington et al.	N/A	N/A
2003/0082719	12/2002	Schumacher et al.	N/A	N/A
2003/0093818	12/2002	Belmont et al.	N/A	N/A
2003/0219463	12/2002	Falkenburg et al.	N/A	N/A
2004/0038886	12/2003	Finney et al.	N/A	N/A
2004/0115198	12/2003	Spies et al.	N/A	N/A
2004/0259196	12/2003	Zipori et al.	N/A	N/A
2005/0048055	12/2004	Newell et al.	N/A	N/A
2005/0129671	12/2004	Cooper et al.	N/A	N/A
2005/0238626	12/2004	Yang et al.	N/A	N/A
2006/0247420	12/2005	Coukos et al.	N/A	N/A
2006/0093605	12/2005	Campana et al.	N/A	N/A
2006/0166314	12/2005	Voss et al.	N/A	N/A
2006/0263334	12/2005	Finn et al.	N/A	N/A
2006/0269529	12/2005	Niederman et al.	N/A	N/A
2007/0066802	12/2006	Geiger	N/A	N/A
2007/0077241	12/2006	Spies et al.	N/A	N/A
2007/0116690	12/2006	Yang et al.	N/A	N/A
2008/0199424	12/2007	Yang et al.	N/A	N/A
2008/0292549	12/2007	Jakobsen et al.	N/A	N/A
2008/0292602	12/2007	Jakobsen et al.	N/A	N/A
2009/0053184	12/2008	Morgan et al.	N/A	N/A
2009/0202501	12/2008	Zhang et al.	N/A	N/A
2009/0226404	12/2008	Schuler et al.	N/A	N/A
2009/0304657	12/2008	Morgan et al.	N/A	N/A
2009/0324566	12/2008	Shiku et al.	N/A	N/A
2010/0009863	12/2009	Himmler et al.	N/A	N/A
2010/0015113	12/2009	Restifo et al.	N/A	N/A
2010/0029749	12/2009	Zhang et al.	N/A	N/A
2010/0055117	12/2009	Krackhardt et al.	N/A	N/A
2010/0104556	12/2009	Blankenstein et al.	N/A	N/A
2010/0105136	12/2009	Carter et al.	N/A	N/A
2010/0135974	12/2009	Eshhar et al.	N/A	N/A
2010/0143315	12/2009	Voss et al.	N/A	N/A
2010/0178276	12/2009	Sadelain et al.	N/A	N/A
2010/0189728	12/2009	Schendel et al.	N/A	N/A
2011/0158957	12/2010	Bonini et al.	N/A	N/A
2012/0252742	12/2011	Kranz et al.	N/A	N/A
2012/0294857	12/2011	Sentman et al.	N/A	N/A

2012/0302466	12/2011	Sentman et al.	N/A	N/A
2013/0011375	12/2012	Chen	N/A	N/A
2013/0323214	12/2012	Gottschalk et al.	N/A	N/A
2014/0004132	12/2013	Brenner et al.	N/A	N/A
2019/0338011	12/2018	Tong et al.	N/A	N/A

FOREIGN PATENT DOCUMENTS

Patent No.	Application Date	Country	CPC
4408999	12/1994	DE	N/A
19540515	12/1996	DE	N/A
10259713	12/2003	DE	N/A
0340793	12/1994	EP	N/A
0499555	12/1999	EP	N/A
0574512	12/2002	EP	N/A
1226244	12/2003	EP	N/A
0871495	12/2004	EP	N/A
1075517	12/2005	EP	N/A
1932537	12/2007	EP	N/A
1765860	12/2007	EP	N/A
2186825	12/2009	EP	N/A
1791865	12/2009	EP	N/A
H05176760	12/1992	JP	N/A
WO 1991018019	12/1990	WO	N/A
WO 1992015322	12/1991	WO	N/A
WO 1994024282	12/1993	WO	N/A
WO 1996015238	12/1995	WO	N/A
WO 1996013584	12/1995	WO	N/A
WO 1998018809	12/1997	WO	N/A
WO 1998041613	12/1997	WO	N/A
WO 2000031239	12/1999	WO	N/A
WO 2000014257	12/1999	WO	N/A
WO 2001092291	12/2000	WO	N/A
2001091625	12/2000	WO	N/A
WO 02/068615	12/2001	WO	N/A
WO 2004056845	12/2003	WO	N/A
WO 2006103429	12/2005	WO	N/A
WO 2006060878	12/2005	WO	N/A
WO 2009059804	12/2008	WO	N/A
WO 2009091826	12/2008	WO	N/A
WO 2010012829	12/2009	WO	N/A
WO 2010025177	12/2009	WO	N/A
WO 2010058023	12/2009	WO	N/A
WO 2010088160	12/2009	WO	N/A
WO 2010037395	12/2009	WO	N/A
WO 2010107400	12/2009	WO	N/A
WO 2011059836	12/2010	WO	N/A
WO 2012050374	12/2011	WO	N/A
WO 2013166051	12/2012	WO	N/A

OTHER PUBLICATIONS

Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, Biassoni R, Moretta L. Activating receptors and coreceptors involved in human natural killer cell-mediated cytotoxicity. *Annual review of immunology*. Apr. 2001;19(1):197-223. cited by applicant

Bruhns P, Marchetti P, Fridman WH, Vivier E, Daëron M. Differential roles of N- and C-terminal immunoreceptor tyrosine-based inhibition motifs during inhibition of cell activation by killer cell inhibitory receptors. *The Journal of Immunology*. Mar. 15, 1999;162(6):3168-75. cited by applicant

Diefenbach A, Raulet DH. The innate immune response to tumors and its role in the induction of T-cell immunity. *Immunological reviews*. Oct. 2002;188(1):9-21. cited by applicant

Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. *science*. Jul. 30, 1999;285(5428):727-9. cited by applicant

Gilham DE, O'Neil A, Hughes C, Guest RD, Kirillova N, Lehane M, Hawkins RE. Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3 ζ -based chimeric immune receptors. *Journal of immunotherapy*. Mar. 1, 2002;25(2):139-51. cited by applicant

Houchins JP, Yabe T, McSherry C, Bach FH. DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells. *The Journal of experimental medicine*. Apr. 1, 1991;173(4):1017-20. cited by applicant

Ho WY, Blattman JN, Dossett ML, Yee C, Greenberg PD. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. *Cancer cell*. May 1, 2003;3(5):431-7. cited by applicant

Lowin-Kropf B, Shapiro VS, Weiss A. Cytoskeletal polarization of T cells is regulated by an immunoreceptor tyrosine-based activation motif-dependent mechanism. *The Journal of cell biology*. Feb. 23, 1998;140(4):861-71. cited by applicant

Yu TK, Caudell EG, Smid C, Grimm EA. IL-2 activation of NK cells: involvement of MKK1/2/ERK but not p38 kinase pathway. *The Journal of Immunology*. Jun. 15, 2000;164(12):6244-51. cited by applicant

Abken H, et al. "Immune response manipulation: recombinant immunoreceptors endow T-cells with predefined specificity," *Curr Pharm Des*. 2003;9(24):1992-2001. cited by applicant

Beecham EJ, et al. "Coupling CD28 co-stimulation to immunoglobulin T-cell receptor molecules: the dynamics of T-cell proliferation and death," *J Immunother*. Nov.-Dec. 2000;23(6):631-42. cited by applicant

Beecham EJ, et al. 'Dynamics of tumor cell killing by human T lymphocytes armed with an anti-carcinoembryonic antigen chimeric immunoglobulin T-cell receptor.' *J Immunother*. May-Jun. 2000;23(3):332-43. cited by applicant

Billadeau DD, et al. 'NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway.' *Nat Immunol*. Jun. 2003;4(6):557-64. Epub May 11, 2003. cited by applicant

Brocker T, et al. "Adoptive tumor immunity mediated by lymphocytes bearing modified antigen-specific receptors," *Adv Immunol*. 1998;68:257-69. cited by applicant

Calogero A, et al. "Recombinant T-cell receptors: an immunologic link to cancer therapy," *J Immunother*. Jul.-Aug. 2000;23(4):393-400. cited by applicant

Cooper LJ, et al. "Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1," *Blood*. Feb. 15, 2005;105(4):1622-31. cited by applicant

Costa GL, et al. "Targeting rare populations of murine antigen-specific T lymphocytes by retroviral transduction for potential application in gene therapy for autoimmune disease," *J Immunol*. Apr. 1, 2000;164(7):3581-90. cited by applicant

Dall P, et al. 'In vivo cervical cancer growth inhibition by genetically engineered cytotoxic T cell'

Cancer Immunol Immunother. Jan. 2005;54(1):51-60. cited by applicant

Daly T, et al. "Recognition of human colon cancer by T cells transduced with a chimeric receptor gene," Cancer Gene Ther. Feb. 2000;7(2):284-91. cited by applicant

Darcy PK, et al. "Redirected perforin-dependent lysis of colon carcinoma by ex vivo genetically engineered CTL," J Immunol. Apr. 1, 2000;164(7):3705-12. cited by applicant

Eshhar Z, et al. 'Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.' Proc Natl Acad Sci U S A. Jan. 15, 1993;90(2):720-4. cited by applicant

Finney HM, et al. "Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain," J Immunol. Jan. 1, 2004;172(1):104-13. cited by applicant

Finney HM, et al. 'Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product.' J Immunol. Sep. 15, 1998;161(6):2791-7. cited by applicant

Fitzer-Attas CJ, et al. "Tyrosine kinase chimeras for antigen-selective T-body therapy," Adv Drug Deliv Rev. Apr. 6, 1998;31(1-2):171-182. cited by applicant

Garrity D, et al. 'The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure.' Proc Natl Acad Sci U S A. May 24, 2005;102(21):7641-6. Epub May 13, 2005. cited by applicant

Gilham DE, et al. "Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3zeta-based chimeric immune receptors," J Immunother. Mar.-Apr. 2002;25(2):139-51. cited by applicant

Groh V, et al. "Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells," Nat Immunol. Mar. 2001;2(3):255-60. cited by applicant

Guest RD, et al. "The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens," J Immunother. May-Jun. 2005;28(3):203-11. cited by applicant

Haynes NM, et al. 'Redirecting Mouse CTL Against Colon Carcinoma: Superior Signaling Efficacy of Single-Chain Variable Domain Chimeras Containing TCR- ζ vs Fc ϵ RI-y' J Immunol. Jan. 1, 2001;166(1):182-7. cited by applicant

Hege KM, et al. "T-cell gene therapy," Curr Opin Biotechnol. Dec. 1996;7(6):629-34. cited by applicant

Ho WY, et al. "Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction," Cancer Cell. May 2003;3(5):431-7. cited by applicant

Hombach A, et al. "Grafting T cells with tumor specificity: the chimeric receptor strategy for use in immunotherapy of malignant diseases," Hybridoma. Feb. 1999;18(1):57-61. cited by applicant

Imai C, et al. "Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia," Leukemia. Apr. 2004;18(4):676-84. cited by applicant

Imai C, et al. "T-Cell immunotherapy for B-lineage acute lymphoblastic leukemia using chimeric antigen receptors that deliver 4-1BB-mediated costimulatory signals," Blood. Nov. 16, 2003;102(11):66A-67A. cited by applicant

Imai et al. "Genetic modification of T cells for cancer therapy," J Biol Regul Homeost Agents. Jan-Mar. 2004;18(1):62-71. cited by applicant

Junghans RP. "Designer T Cells for Breast Cancer Therapy: Phase I Studies," Beth Israel Deaconess Medical Center, Boston, Massachusetts; 2001. 85 pages. cited by applicant

Lamers CH, et al. "Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer," Cancer Gene Ther. Jul. 2002;9(7):613-23. cited by applicant

Lampson LA. "Beyond inflammation: site-directed immunotherapy," Immunol Today. Jan. 1998;19(1):17-22. cited by applicant

Liao KW, et al. "Design of transgenes for efficient expression of active chimeric proteins on mammalian cells," *Biotechnol Bioeng.* May 20, 2001;73(4):313-23. cited by applicant

Losch FO, et al. 'Activation of T cells via tumor antigen specific chimeric receptors: the role of the intracellular signaling domain.' *Int J Cancer.* Jan. 20, 2003;103(3):399-407. cited by applicant

Ma Q, et al. "Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy," *Prostate.* Sep. 15, 2004;61(1):12-25. cited by applicant

Ma Q, et al. "Genetically engineered T cells as adoptive immunotherapy of cancer," *Cancer Chemother Biol Response Modif.* 2002;20:315-41. cited by applicant

Maher J, et al. 'Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.' *Nat Biotechnol.* Jan. 2002;20(1):70-5. cited by applicant

Meresse B, et al. 'Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease.' *Immunity.* Sep. 2004;21(3):357-66. cited by applicant

Moeller M, et al. 'A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells.' *Cancer Gene Ther.* May 2004;11(5):371-9. cited by applicant

Motmans K, et al. 'Enhancing the tumor-specificity of human T cells by the expression of chimericimmunoglobulin/T cell receptor genes.' *Immunotechnology,* Nov. 1996;2(4): 303-304(2). cited by applicant

Muniappan A, et al. "Ligand-mediated cytolysis of tumor cells: use of heregulin-zeta chimeras to redirect cytotoxic T lymphocytes," *Cancer Gene Ther.* Jan. 2000;7(1):128-34. cited by applicant

Nguyen P, et al. 'Antigen-specific targeting of CD8+ T cells with receptor-modified T lymphocytes.' *Gene Ther.* Apr. 2003;10(7):594-604. cited by applicant

Nguyen P, et al. 'Identification of a murine CD28 dileucine motif that suppresses single-chain chimeric T-cell receptor expression and function.' *Blood.* Dec. 15, 2003;102(13):4320-5. Epub Aug. 28, 2003. cited by applicant

Pardoll DM. "Tumor reactive T cells get a boost," *Nat Biotechnol.* Dec. 2002;20(12):1207-8. cited by applicant

Patel SD et al. "T-cell killing of heterogenous tumor or viral targets with bispecific chimeric immune receptors," *Cancer Gene Ther.* Aug. 2000;7(8):1127-34. cited by applicant

Patel SD, et al. "Impact of chimeric immune receptor extracellular protein domains on T cell function," *Gene Ther.* Mar. 1999;6(3):412-9. cited by applicant

Pinthus JH, Eshhar Z. The T-body approach: towards cancer immuno-gene therapy. In: Stuhler G, Walden P, editors. *Cancer Immune Therapy: Current and Future Strategies.* John Wiley & Sons; 2002. p. 287-98. cited by applicant

Pule M, et al. "Artificial T-cell receptors," *Cytotherapy.* 2003;5(3):211-26. cited by applicant

Regueiro JR, Martín-Fernández JM, Melero I. Immunity and gene therapy: benefits and risks. *Inmunología.* 2004;23(1):56-62. cited by applicant

Rössig C, et al. "Chimeric T-cell receptors for the targeting of cancer cells," *Acta Haematol.* 2003;110(2-3):154-9. cited by applicant

Rössig C, et al. "Genetic modification of T lymphocytes for adoptive immunotherapy," *Mol Ther.* Jul. 2004;10(1):5-18. cited by applicant

Rössig C1, et al. "Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy," *Blood.* Mar. 15, 2002;99(6):2009-16. cited by applicant

Schumacher TN. "T-cell-receptor gene therapy," *Nat Rev Immunol.* Jul. 2002;2(7):512-9. cited by applicant

Uherek C, et al. "Chimeric antigen receptors for the retargeting of cytotoxic effector cells," *J Hematother Stem Cell Res.* Aug. 2001;10(4):523-34. cited by applicant

Verneris MR, et al. 'Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells.' *Blood.* Apr. 15, 2004;103(8):3065-72. Epub Nov. 20, 2003. cited by applicant

Weijtens ME, et al. "A retroviral vector system 'STITCH' in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytes," *Gene Ther.* Sep. 1998;5(9):1195-203. cited by applicant

Weijtens ME, et al. "Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production," *Gene Ther.* Jan. 2000;7(1):35-42. cited by applicant

Weijtens MEM. "Immune-gene therapy for renal cancer chimeric receptor-mediated lysis of tumor cells," thesis, Erasmus University Rotterdam; 2001. 128 pages. cited by applicant

Willemsen RA, et al. "Genetic engineering of T cell specificity for immunotherapy of cancer," *Hum Immunol.* Jan. 2003;64(1):56-68. cited by applicant

Wu J, et al. 'An activating immunoreceptor complex formed by NKG2D and DAP10.' *Science.* Jul. 30, 1999;285(5428):730-2. cited by applicant

Report Listing Estimated New Cancer Cases and Deaths by Sex, United States American Cancer Society, Surveillance and Health Policy (2009). cited by applicant

Baba et al., "N-Linked Carbohydrate on Human Leukocyte Antigen-C and Recognition by natural Killer Cell Inhibitory Receptors", *Human Immunology* 20000 61:1202-1218. cited by applicant

Barber et al., "Chimeric NKG2D Receptor-Bearing T Cells as Immunotherapy for Ovarian Cancer," *Cancer Research*, vol. 67, No. 10 (2007). cited by applicant

Barber et al., "Chimeric NKG2D Receptor-Expressing T Cells as an Immunotherapy for Multiple Myeloma," *Experimental Hematology*, pp. 1-11 (2008). cited by applicant

Basu et al., "Estradiol Regulates MICA Expression in Human Endometrial Cells," *Clinical Immunology*, vol. 129, pp. 325-332 (2008). cited by applicant

Bauer et al., Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA, *Science* 285(5428): 727-729, 1999. cited by applicant

Belakova et al., DNA vaccines: are they still just a powerful tool for the future? *Arch Immunol Ther Exp. (Warsz)*, 55(6): 387-398, 2007. cited by applicant

Boll et al., "Heat Shock protein 90 Inhibitor BIIB021 (CNF2024) Depletes NF-kB and Sensitizes Hodgkin Lymphoma Cells for Natural Killer Cell-Mediated Cytotoxicity," *Clinical Cancer Research*, vol. 15, No. 16 (2009). cited by applicant

Bonini et al., "HSV-TK Gene Transfer into Donor Lymphocytes for Control of Allogeneic Graft-Versus-Leukemia", *Science* 1997 276:1720-1724. cited by applicant

Cambier. "Antigen and Fc receptor signaling. The awesome power of the immunoreceptor tyrosine-based activation motif (ITAM)," *J Immunol.* Oct. 1, 1995;155(7):3281-5. cited by applicant

Chansac et al., "Potentiation of NK Cell-Mediated Cytotoxicity in Human Lung Adenocarcinoma: Role of NKG2D-Dependent Pathway," *International Immunology*, vol. 20, No. 7, pp. 801-810 (2008). cited by applicant

Chen et al., "NKG2D Ligands Expression and NKG2D-Mediated Cytotoxicity in Human Laryngeal Squamous Carcinoma Cells," *Scandinavian Journal of Immunology*, vol. 67, pp. 441-447 (2008). cited by applicant

Clay et al., "Efficient Transfer of a Tumor Antigen-Reactive TCR to Human Peripheral Blood Lymphocytes Confers Anti-Tumor Reactivity", *The Journal of Immunology* 1999 163:507-513. cited by applicant

Diefenbach et al., "Innate immune recognition by stimulatory immunoreceptors," *Current Opinion in Immunology*, 15(1): 37-44, 2003. cited by applicant

Diefenbach et al., The innate immune response to tumors and its role in the induction of T-cell immunity, *Immunol Rev.* 188: 9-21, 2002. cited by applicant

Duan et al., "Clinical Significance of the Immunostimulatory MHC Class II Chain-Related Molecule A and NKG2D Receptor on NK Cells in Pancreatic Cancer," *Medical Oncology* (2010). cited by applicant

Dulphy et al., "NKG2D Ligands Expression and NKG2D-Mediated NK Activity in Sezary

Patients,” *Journal of Investigative Dermatology*, vol. 129, pp. 359-364 (2009). cited by applicant

Eisele et al., “TGF-B and Metalloproteinases Differentially Suppress NKG2D Ligand Surface Expression on Malignant Glioma Cells,” *Brain*, vol. 129, pp. 2416-2425 (2006). cited by applicant

Friese et al., “MICA/NKG2D-Mediated Immunogene Therapy of Experimental Gliomas,” *Cancer Research*, vol. 63, pp. 8996-9006 (2003). cited by applicant

Gilham et al., “Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3zeta-based chimeric immune receptors,” *J. Immunother*, Mar.-Apr. 2002;25(2): 139-151, 2002. cited by applicant

Girlanda et al., “MICA Expressed by Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance Plasma Cells Costimulates Pamidronate-Activated $\gamma\delta$ Lymphocytes,” *Cancer Research*, vol. 65, No. 16, pp. 7502-7508 (2005). cited by applicant

Gonzalez et al., “Genetic engineering of cytolytic T lymphocytes for adoptive T-cell therapy of neuroblastoma”, *J Gene Med* 2004 6:704-711. cited by applicant

Groh et al., “Broad Tumor-Associated Expression and Recognition by Tumor-Derived $\gamma\delta$ T Cells of MICA and MICB,” *Proceedings of the National Academy of Sciences*, vol. 96, pp. 6879-6884 (1999). cited by applicant

Heuser et al., “T-cell activation by recombinant immunoreceptors: impact of the intracellular signalling domain on the stability of receptor expression and antigen-specific activation of grafted T-cells,” *Gene Therapy* 10: 1408-1419, 2003. cited by applicant

Houchins et al., “DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells,” *J Exp. Med.* 173(4): 1017-1020, 1991. cited by applicant

Inagaki et al., “Expression of the ULBP Ligands for NKG2D by B-NHL Cells Plays an Important Role in Determining Their Susceptibility to Rituximab-Induced ADCC,” *International Journal of Cancer*, vol. 125, pp. 212-221 (2009). cited by applicant

Jinushi et al., “Expression and Role of MICA and MICB in Human Hepatocellular Carcinomas and Their Regulation by Retinoic Acid,” *International Journal of Cancer*, vol. 104, pp. 354-361 (2003). cited by applicant

Liu et al., “MICA and MICB Overexpression in Oral Squamous Cell Carcinoma,” *Journal of Oral Pathology and Medicine*, vol. 36, pp. 43-47 (2007). cited by applicant

Lowin-Kropf et al., “Cytoskeletal polarization of T cells is regulated by an immunoreceptor tyrosine-based activation motif-dependent mechanism,” *J Cell Biol.* 140(4): 861-871, 1998. cited by applicant

Madjd et al., “Upregulation of MICA on High-Grade Invasive Operable Breast Carcinoma,” *Cancer Immunity*, vol. 7, pp. 1-10 (2007). cited by applicant

Mittendorf et al., “Breast cancer vaccines: promise for the future or pipe dream?” *Cancer*, 110(8): 1677-1686, 2007. cited by applicant

Miyazaki et al., “The Liposome-Incorporating Cell Wall Skeleton of Mycobacterium Bovis Bacillus Calmette-Guein can Directly Enhance the Susceptibility of Cancer Cells to Lymphokine-Activated Killer Cells Through Up-Regulation of Natural-Killer Group 2, Member D Ligands,” *BJU International*, pp. 1-7 (2011). cited by applicant

Moingeon et al., “Human natural killer cells and mature T lymphocytes express identical CD3 Zeta subunits as defined by cDNA cloning and sequence analysis”, *Eur. J. Immunol.* 1990 20:1741-1745. cited by applicant

NCBI Accession No. AB055881 [gi:17221621] with Revision History—Dec. 1, 2001. cited by applicant

NCBI Accession No. AF019562 [gi:2905993] with Revision History—Jan. 26, 1999. cited by applicant

NCBI Accession No. AF072845 [gi:5690195], 1999. cited by applicant

NCBI Accession No. AF098358 [gi:4139191], 2000. cited by applicant

NCBI Accession No. AF133299 [gi:6651064], 2000. cited by applicant

NCBI Accession No. AF461157 [gi:18182677], 2002. cited by applicant

NCBI Accession No. AF461811 [gi:18182679], Jan. 17, 2002. cited by applicant

NCBI Accession No. AF461812 [gi:18182681], 2002. cited by applicant

NCBI Accession No. AJ001383 [gi:3647278] with Revision History—Sep. 22, 1998. cited by applicant

NCBI Accession No. AJ001684 [gi:2980858] with Revision History—Sep. 4, 1998-Nov. 14, 2006. cited by applicant

NCBI Accession No. AJ225109 [gi:4493701] with Revision History—Mar. 15, 1999. cited by applicant

NCBI Accession No. AJ271694 [gi:6900101] with Revision History—Feb. 2, 2000-Nov. 14, 2006. cited by applicant

NCBI Accession No. AJ312373 [gi:14599393] with Revision History—Jul. 3, 2001-Apr. 15, 2005. cited by applicant

NCBI Accession No. BC-30937 [gi:24980984] with Revision History—Jun. 25, 2004-Jul. 15, 2006. cited by applicant

NCBI Accession No. M33195 [gi:182487] with Revision History—Oct. 2, 1992-Apr. 27, 1993. cited by applicant

NCBI Accession No. NM_016509 with Revision History—Mar. 2, 2006-Nov. 18, 2006. cited by applicant

NCBI Accession No. NM_001781 [gi:4502680] with Revision History—Mar. 30, 2006-Nov. 17, 2006. cited by applicant

NCBI Accession No. NM_001782 [gi:4502682] with Revision History—Aug. 13, 2006-Mar. 11, 2007. cited by applicant

NCBI Accession No. NM_002262 [gi:7669497] with Revision History—Feb. 5, 2006-Nov. 17, 2006. cited by applicant

NCBI Accession No. NM_002543 [gi:37595562] with Revision History—Aug. 13, 2006-Feb. 18, 2007. cited by applicant

NCBI Accession No. NM_007334 [gi:7669498] with Revision History—Feb. 5, 2006-Nov. 17, 2006. cited by applicant

NCBI Accession No. NM_016523 [gi:7705573] with Revision History—Apr. 22, 2005-Feb. 27, 2007. cited by applicant

NCBI Accession No. NM_198053 [gi:37595564] with Revision History—Oct. 15, 2006-Jan. 14, 2007. cited by applicant

NCBI Accession No. U11276 [gi:538270] with Revision History—Sep. 16, 1994-Sep. 23, 1994. cited by applicant

Nowbakht et al., “Ligands for Natural Killer Cell-Activating Receptors are Expressed Upon the Maturation of Normal Myelomonocytic Cells but at Low Levels in Acute Myeloid Leukemias,” *Blood*, vol. 105, pp. 3615-3622 (2005). cited by applicant

Nuckel et al., “The Prognostic Significance of Soluble NKG2D Ligands in B-Cell Chronic Lymphocytic Leukemia,” *Leukemia*, vol. 24, pp. 1152-1159 (2010). cited by applicant

Oelke et al., “Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells”, *Nature Medicine* 2003 9(5):619-624. cited by applicant

Reilly, R. Todd, “Proper Costimulation of Tumor-Reactive T Lymphocytes May Provide a Key to Unlock Their Antitumor Activity”, *Cancer Biology & Therapy* 2003 2(5):587-588. cited by applicant

Rosen, et al. “A Structural basis for the association of DAP12 with mouse, but not human, NKG2D,” *J Immunol.* Aug. 15, 2004;173(4):2470-8. cited by applicant

Salih et al., “Functional Expression and Release of Ligands for the Activating Immunoreceptor NKG2D in Leukemia,” *Blood*, vol. 102, pp. 1389-1396 (2003). cited by applicant

Sconocchia et al., "The Antileukemia Effect of HLA-Matched NK and NK-T Cells in Chronic Myelogenous Leukemia Involves NKG2D-Target-Cell Interactions," Blood, vol. 106, pp. 3666-3672 (2005). cited by applicant

Stancovski et al., "Targeting of T Lymphocytes to Neu/HER2-Expressing Cells Using Chimeric Single Chain Fv Receptors", J. Immunol 1993 151(11):6577-6582. cited by applicant

Stevens et al., "Generation of Tumor-Specific CTLs from Melanoma Patients by Using Peripheral Blood Stimulated with Allogeneic Melanoma Tumor Cell Lines", J. Immunol 1995 154:762-771. cited by applicant

Suzuki et al., "The Anticancer Effect of $\gamma\delta$ T-Cells is Enhanced by Valproic Acid-Induced Up-Regulation of NKG2D Ligands," Anticancer Research, vol. 30, pp. 4509-4514 (2010). cited by applicant

Textor et al., "Activating NK Cell Receptor Ligands are Differentially Expressed During Progression to Cervical Cancer," International Journal of Cancer, vol. 123, pp. 2343-2353 (2008). cited by applicant

Thomis et al., "A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease", Blood 2001 97(5):1249-1257. cited by applicant

Ulmer et al., "Gene-based vaccines: recent technical and clinical advances," Trends Mol Med. 12(5): 216-222, 2006. cited by applicant

Vetter et al., "Expression of Stress-Induced MHC Class I Related Chain Molecules on Human Melanoma," The Journal of Investigative Dermatology, vol. 118, No. 4, (2002). cited by applicant

Wilson, et al. "DAP12 and KAP10 (DAP10)—novel transmembrane adapter proteins of the CD3zeta family," Immunol Res. 2000;22(1):21-42. cited by applicant

Wu et al., "Prevalent Expression of the Immunostimulatory MHC Class I Chain-Related Molecule is Counteracted By Shedding in a Prostate Cancer," The Journal of Clinical Investigation, vol. 114, No. 4 (2004). cited by applicant

Wu et al., "An activating immunoreceptor complex formed by NKG2D and DAP10," Science, 285: 730-732, 1999. cited by applicant

Xu et al., "Clinicopathological Significance of Major Histocompatibility Complex Class I-Related Chain A and B Expression in Thyroid Cancer," The Journal of Clinical Endocrinology and Metabolism, vol. 91, No. 7, pp. 2704-2712 (2006). cited by applicant

Zhang et al., "Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy", Blood 2005 106(5):1544-1551. cited by applicant

Carbone, et al. "HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells," Blood. Jan. 1, 2005;105(1):251-8. cited by applicant

Primary Examiner: Singh; Anoop K

Assistant Examiner: Montanari; David A

Attorney, Agent or Firm: Baker, Donelson, Bearman, Caldwell & Berkowitz PC

Background/Summary

INTRODUCTION (1) This application is a divisional of U.S. patent application Ser. No. 16/458,740 filed Jul. 1, 2019 (now U.S. Pat. No. 11,339,199), which is a divisional of U.S. patent application Ser. No. 14/600,799 filed Jan. 20, 2015, (now U.S. Pat. No. 10,336,804), which is a continuation of U.S. patent application Ser. No. 12/407,440 filed Mar. 19, 2009 (now abandoned), which is a Continuation-in-part of U.S. patent application Ser. No. 11/575,878 filed Apr. 19, 2007

(now U.S. Pat. No. 7,994,298), which is a National Stage Entry of international Patent Cooperation Treaty Application No. PCT/US05/31100 filed Aug. 31, 2005, which claims priority to U.S. Provisional Application No. 60/681,782, filed May 17, 2005 and U.S. Provisional Application No. 60/612,836 filed Sep. 24, 2004, each and all of which are incorporated herein by reference in their entireties. (2) This application includes as part of its disclosure a biological sequence listing contained in a file named "11483070000208.txt" having a size of 23,018 bytes that was created May 19, 2022, which is hereby incorporated by reference in its entirety.

BACKGROUND OF THE INVENTION

(1) T cells, especially cytotoxic T cells, play important roles in anti-tumor immunity (Rossing and Brenner (2004) *Mol. Ther.* 10:5-18). Adoptive transfer of tumor-specific T cells into patients provides a means to treat cancer (Sadelain, et al. (2003) *Nat. Rev. Cancer* 3:35-45). However, the traditional approaches for obtaining large numbers of tumor-specific T cells are time-consuming, laborious and sometimes difficult because the average frequency of antigen-specific T cells in periphery is extremely low (Rosenberg (2001) *Nature* 411:380-384; Ho, et al. (2003) *Cancer Cell* 3:431-437; Crowley, et al. (1990) *Cancer Res.* 50:492-498). In addition, isolation and expansion of T cells that retain their antigen specificity and function can also be a challenging task (Sadelain, et al. (2003) *supra*) Genetic modification of primary T cells with tumor-specific immunoreceptors, such as full-length T cell receptors or chimeric T cell receptor molecules can be used for redirecting T cells against tumor cells (Stevens, et al. (1995) *J. Immunol.* 154:762-771; Oelke, et al. (2003) *Nat. Med.* 9:619-624; Stancovski, et al. (1993) *J. Immunol.* 151:6577-6582; Clay, et al. (1999) *J. Immunol.* 163:507-153). This strategy avoids the limitation of low frequency of antigen-specific T cells, allowing for facilitated expansion of tumor-specific T cells to therapeutic doses.

(2) Natural killer (NK) cells are innate effector cells serving as a first line of defense against certain viral infections and tumors (Biron, et al. (1999) *Annu. Rev. Immunol.* 17:189-220; Trinchieri (1989) *Adv. Immunol.* 47:187-376). They have also been implicated in the rejection of allogeneic bone marrow transplants (Lanier (1995) *Curr. Opin. Immunol.* 7:626-631; Yu, et al. (1992) *Annu. Rev. Immunol.* 10:189-214). Innate effector cells recognize and eliminate their targets with fast kinetics, without prior sensitization. Therefore, NK cells need to sense if cells are transformed, infected, or stressed to discriminate between abnormal and healthy tissues. According to the missing self phenomenon (Kärre, et al. (1986) *Nature* (London) 319:675-678), NK cells accomplish this by looking for and eliminating cells with aberrant major histocompatibility complex (MHC) class I expression; a concept validated by showing that NK cells are responsible for the rejection of the MHC class I-deficient lymphoma cell line RMA-S, but not its parental MHC class I-positive line RMA.

(3) Inhibitory receptors specific for MHC class I molecules have been identified in mice and humans. The human killer cell Ig-like receptors (KIR) recognize HLA-A, -B, or -C; the murine Ly49 receptors recognize H-2K or H-2D; and the mouse and human CD94/NKG2 receptors are specific for Qa1.sup.b or HLA-E, respectively (Long (1999) *Annu. Rev. Immunol.* 17:875-904; Lanier (1998) *Annu. Rev. Immunol.* 16:359-393; Vance, et al. (1998) *J. Exp. Med.* 188:1841-1848).

(4) Activating NK cell receptors specific for classic MHC class I molecules, nonclassic MHC class I molecules or MHC class I-related molecules have been described (Bakker, et al. (2000) *Hum. Immunol.* 61:18-27). One such receptor is NKG2D (natural killer cell group 2D) which is a C-type lectin-like receptor expressed on NK cells, $\gamma\delta$ -TcR.sup.+ T cells, and CD8.sup.+ $\alpha\beta$ -TcR.sup.+ T cells (Bauer, et al. (1999) *Science* 285:727-730). NKG2D is associated with the transmembrane adapter protein DAP10 (Wu, et al. (1999) *Science* 285:730-732), whose cytoplasmic domain binds to the p85 subunit of the PI-3 kinase.

(5) In humans, two families of ligands for NKG2D have been described (Bahram (2000) *Adv. Immunol.* 76:1-60; Cerwenka and Lanier (2001) *Immunol. Rev.* 181:158-169). NKG2D binds to the polymorphic MHC class I chain-related molecules (MIC)-A and MICB (Bauer, et al. (1999) *supra*).

These are expressed on many human tumor cell lines, on several freshly isolated tumor specimens, and at low levels on gut epithelium (Groh, et al. (1999) *Proc. Natl. Acad. Sci. USA* 96:6879-6884). NKG2D also binds to another family of ligands designated the UL binding proteins (ULBP)-1, -2, and -3 molecules (Cosman, et al. (2001) *Immunity* 14:123-133; Kubin, et al. (2001) *Eur. J. Immunol.* 31:1428-1437). Although similar to class I MHC molecules in their $\alpha 1$ and $\alpha 2$ domains, the genes encoding these proteins are not localized within the MHC. Like MIC (Groh, et al. (1996) supra), the ULBP molecules do not associate with β .sub.2-microglobulin or bind peptides. The known murine NKG2D-binding repertoire encompasses the retinoic acid early inducible-1 gene products (RAE-1) and the related H60 minor histocompatibility antigen (Cerwenka, et al. (2000) *Immunity* 12:721-727; Diefenbach, et al. (2000) *Nat. Immunol.* 1:119-126). RAE-1 and H60 were identified as ligands for mouse NKG2D by expression cloning these cDNA from a mouse transformed lung cell line (Cerwenka, et al. (2000) supra). Transcripts of RAE-1 are rare in adult tissues but abundant in the embryo and on many mouse tumor cell lines, indicating that these are oncofetal antigens.

(6) Recombinant receptors containing an intracellular domain for activating T cells and an extracellular antigen-binding domain, which is typically a single-chain fragment of a monoclonal antibody and is specific for a tumor-specific antigen, are known in the art for targeting tumors for destruction. See, e.g., U.S. Pat. No. 6,410,319.

(7) Baba et al. ((2000) *Hum. Immunol.* 61:1202-18) teach KIR2DL1-CD3 zeta chain chimeric proteins. Further, WO 02/068615 suggests fusion proteins of NKG2D containing the external domain of NKG2D with a distinct DAP10 interacting domain or with cytoplasmic domains derived from other signaling molecules, for example CD28, for use in engineering cells that respond to NKG2D ligands and potentially create a system with enhanced signaling capabilities.

(8) U.S. Pat. No. 5,359,046 discloses a chimeric DNA sequence encoding a membrane bound protein, wherein the chimeric DNA comprises a DNA sequence encoding a signal sequence which directs the membrane bound protein to the surface membrane; a DNA sequence encoding a non-MHC restricted extracellular binding domain of a surface membrane protein selected from the group consisting of CD4, CD8, IgG and single-chain antibody that binds specifically to at least one ligand, wherein said ligand is a protein on the surface of a cell or a viral protein; a transmembrane domain from a protein selected from the group consisting of CD4, CD8, IgG, single-chain antibody, the CD3 zeta chain, the CD3 gamma chain, the CD3 delta chain and the CD3 epsilon chain; and a cytoplasmic signal-transducing domain of a protein that activates an intracellular messenger system selected from the group consisting of the CD3 zeta chain, the CD3 gamma chain, the CD3 delta chain and the CD3 epsilon chain, wherein the extracellular domain and cytoplasmic domain are not naturally joined together and the cytoplasmic domain is not naturally joined to an extracellular ligand-binding domain, and when the chimeric DNA is expressed as a membrane bound protein in a selected host cell under conditions suitable for expression, the membrane bound protein initiates signaling in the host cell.

SUMMARY OF THE INVENTION

(9) The present invention is a nucleic acid construct for expressing a chimeric receptor to reduce or eliminate a tumor. The nucleic acid construct contains a first nucleic acid sequence encoding a promoter operably linked to a second nucleic acid sequence encoding a chimeric receptor protein comprising a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor having an immunoreceptor tyrosine-based activation motif of SEQ ID NO:1. The invention also embraces a vector and an isolated host cell harboring the nucleic acid construct and a nucleic acid construct further including a suicide gene.

(10) The present invention also embraces methods for reducing or eliminating tumors and decreasing the regulatory T cell population. These methods involve transducing an isolated T cell with a nucleic acid construct containing a first nucleic acid sequence encoding a promoter operably linked to a second nucleic acid sequence encoding a chimeric receptor protein comprising a C-type

lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor having an immunoreceptor tyrosine-based activation motif of SEQ ID NO:1 so that the chimeric receptor is expressed on the surface of the T cell. The transduced T cell is subsequently injected into a subject in need of treatment thereby decreasing the regulatory T cell population in the subject and reducing or eliminating tumors.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) FIG. 1 illustrates chimeric NK receptors exemplified herein. Extracellular (EC), transmembrane (TM), and cytoplasmic (Cyp) portions are indicated. Wild-type (WT) and chimeric (CH) forms of the receptors are indicated, wherein NH.sub.2 denotes the N-terminus and COOH denotes the C-terminus.

(2) FIGS. 2A to 2E show specific lysis of target cells by gene-modified primary T cells. Effector T cells modified with vector only (shaded diamond), wild-type NKG2D (open square), murine chimeric NKG2D (shaded square), wild-type DAP10 (open triangle), murine chimeric DAP10 (shaded triangle), or wild-type DAP12 (open circle) were co-cultured with target cells RMA (Panel A), RMA/Rae-1 β (Panel B), RMA/H60 (Panel C), YAC-1 (Panel D), or EG7 (Panel E) cells, respectively, at ratios from 1:1 to 25:1 in a 4 hour ⁵¹Cr release assay. The data are presented as mean \pm SD and representative of 3 to 5 independent experiments.

DETAILED DESCRIPTION OF THE INVENTION

(3) The present invention embraces a chimeric receptor molecule composed of a natural killer cell receptor and an immune signaling receptor expressed on the surface of a T cell to activate killing of a tumor cell. Nucleic acid sequences encoding the chimeric receptor molecule are introduced into T-cells ex vivo and T-cells that express the chimeric receptor molecule are subsequently injected into a subject in need of treatment. In this manner, the chimeric receptor molecules provide a means for the subject's own immune cells to recognize and activate anti-tumor immunity and establish long-term, specific, anti-tumor responses for treating tumors or preventing regrowth of dormant or residual tumor cells. To prevent potential side effects that may occur from uncontrolled inflammation or response against non-tumor tissue, suicide genes are further introduced into the T-cells expressing the chimeric receptor molecule. The suicide gene is activated by administering an agent, specific for the suicide gene, to the patient thereby eliminating all cells expressing the chimeric receptor molecule.

(4) By way of illustration, murine chimeric receptor molecules composed of NKG2D or Dap10 in combination with a N-terminally attached CD3 ζ were generated and expressed in murine T-cells. NKG2D is a type II protein, in which the N-terminus is located intracellularly (Raulet (2003) *Nat. Rev. Immunol.* 3:781-790), whereas the CD3 ζ chain is type I protein with the C-terminus in the cytoplasm (Weissman, et al. (1988) *Proc. Natl. Acad. Sci. USA* 85:9709-9713). To generate a chimeric NKG2D-CD3 ζ fusion protein, an initiation codon ATG was placed ahead of the coding sequence for the cytoplasmic region of the CD3 ζ chain (without a stop codon TAA) followed by a wild-type NKG2D gene. Upon expression, the orientation of the CD3 ζ portion is reversed inside the cells. The extracellular and transmembrane domains are derived from NKG2D. A second chimeric gene encoding the Dap10 gene followed by a fragment coding for the CD3 ζ cytoplasmic domain was also constructed. The structures of the chimeric and wild-type receptors used are diagrammed in FIG. 1.

(5) To determine whether murine chimeric NKG2D or murine chimeric Dap10 receptors could be expressed in a similar manner as wild-type murine NKG2D or Dap10, a NKG2D gene with an adaptor protein gene (Dap10/Dap12) were co-transfected into Bosc23 cells and NKG2D expression was determined by flow cytometry. To analyze those cells that were transfected, a bicistronic vector

with a green fluorescent protein (GFP) gene controlled by an internal ribosome entry site (IRES) was used. NKG2D surface expression was normalized by gating on the GFP.sup.+ cell population. Like many NK receptors, such as CD94/NKG2C, Ly49D, and Ly49H, NKG2D needs to be associated with adaptor proteins (i.e., Dap10 and/or Dap12) for surface expression (Raulet (2003) supra; Lanier (2003) *Curr. Opin. Immunol.* 15:308-314). Packaging cell Bosc23 did not express either NKG2D or Dap10/Dap12, and transfection with only one of the two components did not give rise to surface expression of NKG2D. However, co-transfection of a NKG2D gene along with an adaptor protein gene led to significant membrane expression of NKG2D. Compared with Dap12, Dap10 transfection resulted in higher NKG2D surface expression. Surface expression of NKG2D after association with chimeric Dap10 adaptor was higher than that with wild-type DAP10. Higher surface expression of NKG2D was also observed after transfection with chimeric NKG2D than with wild-type NKG2D genes, especially when pairing with the Dap12 gene (>5-fold increase in MFI).

(6) Concentrated, high-titer, retroviral vectors (ecotropic) were used to infect C57BL/6 spleen cells, and NKG2D surface expression was determined by flow cytometry seven days after retroviral transduction. Genetic modification of T cells with wild-type Dap10, Dap12 and NKG2D did not significantly increase the surface expression of NKG2D (10-20%) compared to vector alone. In contrast, significantly higher NKG2D expression was observed in T cells modified with either chimeric NKG2D (42%) or chimeric Dap10 (64%). In chimeric Dap10-transduced T cells, the surface-expressed NKG2D molecules were only due to endogenous molecules, whereas both endogenous and exogenous NKG2D molecules were responsible for surface expression in chimeric NKG2D-modified T cells. Taken together, these data indicate that chimeric NKG2D and chimeric Dap10 molecules are expressed in a similar manner as the wild-type molecules and that they increase NKG2D expression on T cells.

(7) To assess whether the murine chimeric DAP10 or murine chimeric NKG2D-transduced T cells were capable of recognizing NKG2D ligands, NKG2D ligand-positive tumor cells (RMA/Rae-1 β , RMA/H60 and YAC-1) were used as targets for chimeric NKG2D-bearing T cells. Chimeric DAP10 or chimeric NKG2D-transduced T cells produced high amounts of IFN- γ (20-30 ng/mL) after co-culture with RMA/Rae-1 β , RMA/H60 or YAC-1 cells (Table 1) but not with RMA cells (no ligands), indicating that these chimeric NKG2D-modified T cells could functionally recognize NKG2D ligand-bearing tumor cells.

(8) TABLE-US-00001

Construct	Media	RMA	RMA/Rae-1 β	RMA/H60	YAC-1	Vector
Only Wild-type	0.01 \pm 0.01	0.10 \pm 0.21	0.04 \pm 0.06	0.05 \pm 0.00	1.08 \pm 1.48	NKG2D*
Chimeric	0.07 \pm 0.08	0.37 \pm 0.34	4.70 \pm 0.78	8.40 \pm 1.60	17.80 \pm 4.60	NKG2D Wild-type
Wild-type	0.01 \pm 0.10	0.11 \pm 0.11	0.04 \pm 0.03	0.09 \pm 0.03	1.43 \pm 1.72	DAP10*
Chimeric	0.49 \pm 0.55	0.82 \pm 0.52	7.50 \pm 4.40	18.60 \pm 7.60	28.70 \pm 8.30	DAP10 Wild-Type
Wild-Type	0.00 \pm 0.01	0.00 \pm 0.01	0.53 \pm 0.67	0.13 \pm 0.10	0.73 \pm 0.09	DAP12.sup.#

*p = 0.74; .sup.#p = 0.56. Data are representative of 3 experiments.

(9) Similarly, chimeric human NKG2D-bearing CD8+ T cells secrete IFN- γ when brought into contact with human tumor cells from breast cancer (MCF-7, T47D), prostate cancer (DU145), pancreatic cancer (Pan-1), and melanoma cancer (A375) (Table 2). T cells were cultured with irradiated tumor cells at a 4:1 ratio for 72 hours and IFN- γ was measured by ELISA. T cells cultured without tumor cells functioned as a media only control which produced no detectable IFN- γ . The specificity of the interaction was evident by comparing chimeric NKG2D transduced T cells to vector only.

(10) TABLE-US-00002

Construct	T47D	MCF-7	Panc-1	DU-145	A375	Vector
Only	(\pm 12.5)	(\pm 3.6)	(\pm 8.0)	(\pm 4.2)	(\pm 44.2)	Wild-type
Wild-type	35.2	43.6	115.8	84.4	200.5	NKG2D*
NKG2D*	(\pm 30.0)	(\pm 9.2)	(\pm 89.8)	(\pm 47.1)	(\pm 79.5)	Chimeric
Chimeric	130.3	2928.3	5028.1	4427.9	2609.2	NKG2D
NKG2D	(\pm 70.4)	(\pm 251.1)	(\pm 407.2)	(\pm 470.1)	(\pm 293.2)	Tumor
Tumor	23.4	17.7	26.6	27.4	11.4	Alone
Alone	(\pm 26.9)	(\pm 8.7)	(\pm 7.5)	(\pm 10.2)	(\pm 17.7)	

(11) In addition, upon NKG2D ligation, chimeric DAP10 or chimeric NKG2D-modified T cells also released significant amounts of proinflammatory chemokines (CCL3 and CCL5), as well as Th1 cytokines, GM-CSF and IL-3, but not Th2 cytokines IL-5 and IL-10. In contrast, wild-type Dap10, Dap12 or NKG2D alone-modified T cells did not show any significant response to the stimulation by RMA/Rae-1 β , RMA/H60 or YAC-1 cells. These data demonstrate that the chimeric molecules led to the direct activation of T cells.

(12) The cytotoxic activity of murine chimeric NKG2D-modified splenic I cells against tumor cells was also determined. Chimeric Dap10 or chimeric NKG2D-transduced T cells were able to lyse NKG2D ligand-expressing target cells (RMA/Rae-1 β , RMA/H60, EG7 and YAC-1) in vitro (FIG. 2, Panels B-E). The specificity of the interaction was apparent from the absence of lysis of YAC-1, EG7, RMA/Rae-1 β and RMA/H60 cells by vector only-transduced T cells, and the lack of lysis of RMA cells by chimeric Dap10 or chimeric NKG2D-modified T cells (FIG. 2, Panel A). Similar to cytokine production, no significant specific lysis of tumor cells was observed by wild-type Dap10 or wild-type NKG2D-modified T cells. T cells transduced with wild-type Dap12 were able to kill target cells that expressed ligands for NKG2D. Activated murine CD8⁺ T cells express NKG2D (associated with Dap10), so expression of Dap12 would allow the endogenous NKG2D to associate with Dap12 and provide a primary activation signal. It is noteworthy that T cells transduced with Dap12 were three- to five-fold less efficient than T cells transduced with chimeric NK receptors at killing tumor cells. The killing of YAC-1 and EG7 tumor cells demonstrates that chimeric NK receptors provide the T cells with a means to kill tumor cells that express endogenous NKG2D ligands.

(13) These data demonstrated the need for NKG2D ligand expression on the target cells. To investigate the role of the NKG2D receptor, it was determined whether blocking antibodies to NKG2D would diminish cytotoxic activity. Chimeric NKG2D-transduced T cells killed RMA/Rae-1 β and EG7 tumor cells and this activity was reduced when anti-NKG2D antibodies were included in the assay. Vector only-transduced T cells were unable to kill the target cells and the activity was not changed with the addition of anti-NKG2D antibodies. While the data indicate that the NKG2D receptor was responsible for the activity in these assays, the chimeric receptors may have, in some way, altered the T cells to kill via their T cell receptor. To address this, the ability of chimeric NKG2D-transduced T cells to kill RMA/Rae-1 β tumor cells was examined. RMA-S cells are deficient in TAP genes and express very low levels of MHC class I molecules on the cell surface and no MHC class II molecules (Aldrich, et al. (1992) *J. Immunol.* 149:3773-3777). Chimeric NKG2D-bearing T cells killed RMA/Rae-1 β tumor cells but not RMA-S cells. Vector-transduced T cells did not kill either RMA-S cell line. Thus, these data indicate that chimeric NKG2D functions via direct NKG2D recognition of its ligand on target cells.

(14) Having shown that chNKG2D-modified T cells could react against NKG2D ligand-positive tumor cells in vitro, the therapeutic potential of chimeric NKG2D-modified T lymphocytes was determined in vivo. Chimeric NKG2D-bearing T cells (10.sup.6) were co-injected with RMA/Rae-1 β tumor cells (10.sup.5) subcutaneously to C57BL/6 mice. T cells transduced with the chimeric NKG2D construct significantly ($P < 0.05$ at days 5-15) inhibited the growth of RMA/Rae-1 β tumors compared with vector-transduced T cells or tumor alone (Table 3). Approximately 36% (4/11) of chimeric NKG2D-bearing T cell-treated mice were tumor-free after 30 days. Chimeric NKG2D-bearing T cells did not show any significant inhibition effects on the growth of wild-type RMA cells, indicating that inhibition of RMA/Rae-1 β tumor growth by chimeric NKG2D T cells was mediated by chimeric NKG2D-Rae-1 β engagement.

(15) TABLE-US-00003 TABLE 3 Tumor Area (Mean mm.sup.2 \pm SEM) T Cells transduced T cells transduced with chimeric with vector only + Day NKG2D + RMA/Rae-1 β RMA/Rae-1 β

RMA/Rae-1 β 0	0.00 \pm 0.00	0.00 \pm 0.00	0.00 \pm 0.00	5	0.00 \pm 0.00	16.14 \pm 2.86	6.79 \pm 1.47	7	3.10 \pm 1.40	38.45 \pm 3.79	28.69 \pm 5.49	9	8.11 \pm 3.09	57.40 \pm 6.43	42.22 \pm 6.38	11	11.84 \pm 5.24	90.31 \pm 11.64	60.60 \pm 12.10	13	14.73 \pm 7.24	127.30 \pm 16.85	82.67 \pm 19.44	15	20.60 \pm 8.32	N.
---------------------	-----------------	-----------------	-----------------	---	-----------------	------------------	-----------------	---	-----------------	------------------	------------------	---	-----------------	------------------	------------------	----	------------------	-------------------	-------------------	----	------------------	--------------------	-------------------	----	------------------	----

D. 110.51 ± 29.07

(16) Results are a summary of three experiments.

(17) In a second and more stringent model, transduced T cells (10.sup.7) were adoptively transferred i.v. into B6 mice one day before s.c. tumor inoculation in the right flank. These chimeric NKG2D-bearing T cells significantly ($P < 0.05$ at days 9-17) suppressed the growth of RMA/Rae-1 β tumors (s.c.) compared with control vector-modified T cells (Table 4). As for the toxicity of treatment with chimeric NKG2D-modified T cells, the animals treated with chimeric NKG2D-bearing T cells did not show any overt evidence of inflammatory damage (i.e., ruffled hair, hunchback or diarrhea, etc.) indicating there was no overt toxicity.

(18) TABLE-US-00004 TABLE 4 Tumor Area (Mean mm.sup.2 \pm SEM) T Cells transduced with Control T cells with Day chimeric NKG2D Vector Only

5	3.06 \pm 1.97	4.41 \pm 2.20	7	12.14 \pm 3.06		
17	17.81 \pm 1.75	9	13.94 \pm 2.85	30.58 \pm 3.87		
11	25.92 \pm 4.77	45.13 \pm 3.27	13	32.11 \pm 5.84		
64.83 \pm 10.45	15	34.39 \pm 9.77	80.72 \pm 13.34	17	37.81 \pm 11.68	96.30 \pm 14.15

(19) Results are a summary of three experiments.

(20) Because the immune system can select for tumor variants, the most effective immunotherapies for cancer are likely going to be those that induce immunity against multiple tumor antigens. Thus, it was tested whether treatment with chimeric NKG2D-bearing T cells could induce host immunity against wild-type tumor cells. Mice that were treated with chimeric NKG2D-bearing T cells and RMA/Rae-1 β tumor cells, and were tumor-free after 30 days, were challenged with RMA tumor cells. These tumor-free mice were resistant to a subsequent challenge of wild-type RMA cells (10.sup.4), whereas all control naïve mice had aggressive tumors (tumor area: ~ 100 mm.sup.2) after 2 weeks (Table 5). This observation indicates that adoptive transfer of chimeric NKG2D-bearing T cells allows hosts to generate T cell memory.

(21) TABLE-US-00005 TABLE 5 Tumor Area (Mean mm.sup.2 \pm SEM) Mice treated with T Cells transduced with chimeric Day NKG2D + RMA/Rae-1 β Naïve Mice

5	0.00 \pm 0.00	1.33 \pm 2.31	7	0.00 \pm 0.00	11.65 \pm 10.20
9	0.00 \pm 0.00	38.75 \pm 8.84	11	0.00 \pm 0.00	60.17 \pm 6.10
13	0.00 \pm 0.00	91.10 \pm 5.59	15	0.00 \pm 0.00	102.81 \pm 17.94
19	0.00 \pm 0.00	146.71 \pm 45.72			

(22) Results are a summary of three experiments.

(23) In similar experiments, human chimeric receptor molecules composed of NKG2D or Dap10 in combination with a N-terminally attached CD3 ζ were generated and expressed in Bosc23 cells. Surface expression of NKG2D was not observed when either human Dap10 or human chimeric NKG2D were transfected alone. However, co-transfection of a human chimeric NKG2D or human chimeric NKG2D-GFP gene along with a wild-type human DAP10 gene or mouse DAP10-GFP construct led to significant membrane expression of NKG2D.

(24) Binding of a human NKG2D fusion protein, composed of NKG2D with an N-terminally attached murine IgG1 Fc portion, to human NKG2D ligand on various tumor cell lines was assessed. Human NKG2D ligand was found to be present on Jurkat (T lymphocyte origin), RPMI8866 (B cell origin), K562 (erythroid origin), Daubi (B cell origin), and U937 (monocyte origin) tumor cell lines. Therefore, like the mouse chimeras, a human chimeric NKG2D construct can functionally recognize NKG2D ligand-bearing tumor cells.

(25) The cytotoxic activity of human chimeric NKG2D-modified T cells against tumor cells was also determined. Human chimeric NKG2D-transduced primary human T cells were able to lyse mastocytoma cell line P815 transduced with human MIC-A (P815/MICA-A) in vitro (Table 6). The specificity of the interaction was apparent from the absence of lysis of wild-type P815 tumor cells and the absence of lysis by vector only-transduced T cells.

(26) TABLE-US-00006 TABLE 6 Tumor Cell Line Specific Lysis (%) P815/MIC-A P815

Effector:Target Ratio	1	5	25	1	5	25	Vector Only	0.0	0.0	0.6	0.0	-0.6	0.0	Human chimeric	5.4	17.3	35.4	-2.5	-0.3	1.1	NKG2D
-----------------------	---	---	----	---	---	----	-------------	-----	-----	-----	-----	------	-----	----------------	-----	------	------	------	------	-----	-------

(27) Further, blocking of human chimeric NKG2D with an anti-NKG2D antibody prevented killing of K562 and RPMI8866 tumor cells by chimeric NKG2D-transduced human T cells (Table 7).

These data demonstrate receptor specificity because a control antibody could not prevent killing.

(28) TABLE-US-00007 TABLE 7 Tumor Cell Line Specific Lysis (%) K562 RPMI8866

Effector:Target Ratio	1	5	25	1	5	25	Vector + control	0.0	0.3	2.3	0.0	1.0	0.0	antibody	Vector + anti-
0.0	0.7	2.1	0.0	1.0	1.3	NKG2D antibody	Human chimeric	3.1	17.6	53.8	9.3	27.4	41.6	NKG2D + control antibody	Human chimeric
1.6	10.1	27.0	1.0	2.5	7.5	NKG2D + anti- NKG2D antibody									

(29) Similar to the mouse studies, human chimeric NKG2D-transduced T cells produced high amounts of IFN- γ (~150-2250 pg/mL) after a 24 hour co-culture with tumor cells that express ligands for NKG2D (i.e., Jurkat, RPMI8866, K652, ECC-01 and P815/MIC-A tumor cells) compared with tumor cells that do not express NKG2D ligands (P815) or T cells incubated alone (Table 8). Vector only-transduced T cells did not produce IFN- γ , except against RPMI8866, indicating another ligand on this cell type for these activated T cells; however, IFN- γ production was almost 10-times as high with the human chimeric NKG2D-bearing T cells. Tumor cells alone produce no detectable IFN- γ .

(30) TABLE-US-00008 TABLE 8 IFN- γ (Mean pg/mL \pm SD) Tumor cell Chimeric Tumor cell

Type	NKG2D	Vector	Only control	P815	30.32 \pm 1.31	15.11 \pm 0.94	5.53 \pm 1.31	P815/MIC-A
140.19 \pm 5.91	9.19 \pm 3.30	2.85 \pm 1.50	Jurkat	182.66 \pm 18.31	7.64 \pm 1.04	2.83 \pm 1.33	RPMI8866	
2239.95 \pm 19.59	280.41 \pm 13.84	2.47 \pm 2.47	K652	2305.46 \pm 75.84	1.91 \pm 0.57	1.82 \pm 1.39	ECC-1	
469.97 \pm 18.79	2.67 \pm 2.67	0.00 \pm 0.00	T Cells only	13.67 \pm 2.55	0.94 \pm 0.54	N. D.		

Amounts Represent the Average of Three Experiments

(31) Chimeric NK cell receptor-bearing T cells are used to provide a means to attack tumor cells by activating host immunity and destroying tumor cells. In addition to tumors expressing NK cell receptor ligand, it is expected that analysis of ligand-deficient tumor cells will also result in tumor cell killing. For example, it has been demonstrated that ectopic expression of NK cell receptor ligands in tumor cell lines results in potent tumor rejection by syngeneic mice (Diefenbach, et al. (2001) *Nature* 413:165-171). However, using these same mice, subsequent challenge with tumor cell lines not expressing the ligands also resulted in tumor rejection. Using the mouse model as described herein, it is expected that NKG2D ligand-negative tumor cell lines, e.g., EL4, a B6 thymoma; RMA, a B6 T lymphoma derived from Rauscher virus-induced RBL-5 cell line (Karre, et al. (1986) *Nature* 319:675-678); and B16-BL6, a B6 melanoma derived from the B16-F0 cell line (Hart (1979) *Am. J. Pathol.* 97:587-600), can be eliminated using the chimeric NK cell receptor-bearing T cells of this invention.

(32) Although specific immunity may be obtained against tumors, local immunosuppressive mechanisms, such as regulatory T cells, prevents the function of tumor-specific T cells. The ability to remove these cells and enhance local anti-tumor immune function would be of great benefit for the treatment of cancer. In addition to activating host anti-tumor immunity, it has also now been found that adoptive transfer of chimeric NK cell receptor-bearing T cells can eliminate host regulatory T cells. Indeed, it was observed that treatment of mice with advanced tumors with chimeric receptor-bearing T cells results in a rapid loss of FoxP3+ T regulatory cells from within the tumor microenvironment (within 3 days) and a destruction of advanced tumor cells. Accordingly, the chimeric NK cell receptors of the invention can also be used to enhance immunotherapy and vaccination approaches via elimination of host regulatory T cells.

(33) Having demonstrated the activation of host anti-tumor immunity and tumor elimination using chimeric NK cell receptors expressed in the T cells of an animal model of cancer and likewise demonstrated human tumor cell killing with human chimeric NK cell receptors, the present invention embraces a nucleic acid construct for expressing a chimeric receptor in host T cells to reduce or eliminate a tumor. The nucleic acid construct contains a first nucleic acid sequence encoding a promoter operably linked to a second nucleic acid sequence encoding a chimeric receptor protein containing a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor having an immunoreceptor tyrosine-based activation motif of SEQ ID NO:1. In general, the C-type lectin-like NK cell type II receptor (or a

protein associated therewith) is located at the C-terminus of the chimeric receptor protein of the present invention whereas the immune signaling receptor is at the N-terminus, thereby facilitating intracellular signal transduction from the C-type lectin-like NK cell type II receptor.

(34) A C-type lectin-like NK cell receptor protein particularly suitable for use in the chimeric receptor of the present invention includes a receptor expressed on the surface of natural killer cells. The receptor can work alone or in concert with other molecules. Ligands for these receptors may or may not be expressed on the surface of one or more tumor cell types, e.g., tumors associated with cancers of the colon, lung, breast, kidney, ovary, cervix, and prostate; melanomas; myelomas; leukemias; and lymphomas (Wu, et al. (2004) *J. Clin. Invest.* 114:60-568; Groh, et al. (1999) *Proc. Natl. Acad. Sci. USA* 96:6879-6884; Pende, et al. (2001) *Eur. J. Immunol.* 31:1076-1086) and are not widely expressed on the surface of cells of normal tissues. Examples of such ligands include, but are not limited to, MIC-A, MIC-B, heat shock proteins, ULBP binding proteins (e.g., ULPBs 1-4), and non-classical HLA molecules such as HLA-E and HLA-G, whereas classical MHC molecules such as HLA-A, HLA-B, or HLA-C and alleles thereof are not generally considered strong ligands of the C-type lectin-like NK cell receptor protein of the present invention. C-type lectin-like NK cell receptors which bind these ligands generally have a type II protein structure, wherein the N-terminal end of the protein is intracellular. Exemplary NK cell receptors of this type include, but are not limited to, Dectin-1 (GENBANK accession number AJ312373 or AJ312372), Mast cell function-associated antigen (GENBANK accession number AF097358), HNKRP-1A (GENBANK accession number U11276), LLT1 (GENBANK accession number AF133299), CD69 (GENBANK accession number NM_001781), CD69 homolog, CD72 (GENBANK accession number NM_001782), CD94 (GENBANK accession number NM_002262 or NM_007334), KLRF1 (GENBANK accession number NM_016523), Oxidised LDL receptor (GENBANK accession number NM_002543), CLEC-1, CLEC-2 (GENBANK accession number NM_016509), NKG2D (GENBANK accession number BC039836), NKG2C (GENBANK accession number AJ001684), NKG2A (GENBANK accession number AF461812), NKG2E (GENBANK accession number AF461157), WUGSC:HDJ0701016.2, or Myeloid DAP12-associating lectin (MDL-1; GENBANK accession number AJ271684). In particular embodiments, the NK cell receptor is human NKG2D (SEQ ID NO:2) or human NKG2C (SEQ ID NO:3).

(35) Similar type I receptors which would be useful in the chimeric receptor of the present invention include NKp46 (e.g., GENBANK accession number AJ001383), NKp30 (e.g., GENBANK accession number AB055881), or NKp44 (e.g., GENBANK accession number AJ225109).

(36) As an alternative to the C-type lectin-like NK cell receptor protein, a protein associated with a C-type lectin-like NK cell receptor protein can be used in the chimeric receptor protein of the present invention. In general, proteins associated with C-type lectin-like NK cell receptor are defined as proteins that interact with the receptor and transduce signals therefrom. Suitable human proteins which function in this manner include, but are not limited to DAP10 (e.g., GENBANK accession number AF072845; SEQ ID NO:4) and DAP12 (e.g., GENBANK accession number AF019562; SEQ ID NO:5).

(37) To the N-terminus of the C-type lectin-like NK cell receptor is fused an immune signaling receptor having an immunoreceptor tyrosine-based activation motif (ITAM), (Asp/Glu)-Xaa-Xaa-Tyr*-Xaa-Xaa-(Ile/Leu)-Xaa.sub.6-8-Tyr*-Xaa-Xaa-(Ile/Leu) (SEQ ID NO:1) which is involved in the activation of cellular responses via immune receptors. Similarly, when employing a protein associated with a C-type lectin-like NK cell receptor, an immune signaling receptor can be fused to the C-terminus of said protein (FIG. 1). Suitable immune signaling receptors for use in the chimeric receptor of the present invention include, but are not limited to, the zeta chain of the T-cell receptor, the eta chain which differs from the zeta chain only in its most C-terminal exon as a result of alternative splicing of the zeta mRNA, the delta, gamma and epsilon chains of the T-cell receptor (CD3 chains) and the gamma subunit of the FcR1 receptor. In particular embodiments, the immune

signaling receptor is CD3-zeta (CD3 ζ) (e.g., GENBANK accession number human NM 198053; SEQ ID NO:6), or human Fc epsilon receptor-gamma chain (e.g., GENBANK accession number M33195; SEQ ID NO:7) or the cytoplasmic domain or a splicing variant thereof.

(38) In particular embodiments, a chimeric receptor of the present invention is a fusion between NKG2D and CD3 ζ or Dap10 and CD3 ζ .

(39) As used herein, a nucleic acid construct or nucleic acid sequence is intended to mean a DNA molecule which can be transformed or introduced into a T cell and be transcribed and translated to produce a product (e.g., a chimeric receptor or a suicide protein).

(40) In the nucleic acid construct of the present invention, the promoter is operably linked to the nucleic acid sequence encoding the chimeric receptor of the present invention, i.e., they are positioned so as to promote transcription of the messenger RNA from the DNA encoding the chimeric receptor. The promoter can be of genomic origin or synthetically generated. A variety of promoters for use in T cells are well-known in the art (e.g., the CD4 promoter disclosed by Marodon, et al. (2003) *Blood* 101(9):3416-23). The promoter can be constitutive or inducible, where induction is associated with the specific cell type or a specific level of maturation.

Alternatively, a number of well-known viral promoters are also suitable. Promoters of interest include the β -actin promoter, SV40 early and late promoters, immunoglobulin promoter, human cytomegalovirus promoter, retrovirus promoter, and the Friend spleen focus-forming virus promoter. The promoters may or may not be associated with enhancers, wherein the enhancers may be naturally associated with the particular promoter or associated with a different promoter.

(41) The sequence of the open reading frame encoding the chimeric receptor can be obtained from a genomic DNA source, a cDNA source, or can be synthesized (e.g., via PCR), or combinations thereof. Depending upon the size of the genomic DNA and the number of introns, it may be desirable to use cDNA or a combination thereof as it is found that introns stabilize the mRNA or provide T cell-specific expression (Barthel and Goldfeld (2003) *J. Immunol.* 171(7):3612-9). Also, it may be further advantageous to use endogenous or exogenous non-coding regions to stabilize the mRNA.

(42) For expression of a chimeric receptor of the present invention, the naturally occurring or endogenous transcriptional initiation region of the nucleic acid sequence encoding N-terminal component of the chimeric receptor can be used to generate the chimeric receptor in the target host. Alternatively, an exogenous transcriptional initiation region can be used which allows for constitutive or inducible expression, wherein expression can be controlled depending upon the target host, the level of expression desired, the nature of the target host, and the like.

(43) Likewise, the signal sequence directing the chimeric receptor to the surface membrane can be the endogenous signal sequence of N-terminal component of the chimeric receptor. Optionally, in some instances, it may be desirable to exchange this sequence for a different signal sequence. However, the signal sequence selected should be compatible with the secretory pathway of T cells so that the chimeric receptor is presented on the surface of the T cell.

(44) Similarly, a termination region can be provided by the naturally occurring or endogenous transcriptional termination region of the nucleic acid sequence encoding the C-terminal component of the chimeric receptor. Alternatively, the termination region can be derived from a different source. For the most part, the source of the termination region is generally not considered to be critical to the expression of a recombinant protein and a wide variety of termination regions can be employed without adversely affecting expression.

(45) As will be appreciated by one of skill in the art, in some instances, a few amino acids at the ends of the C-type lectin-like natural killer cell receptor (or protein associated therewith) or immune signaling receptor can be deleted, usually not more than 10, more usually not more than 5 residues. Also, it may be desirable to introduce a small number of amino acids at the borders, usually not more than 10, more usually not more than 5 residues. The deletion or insertion of amino acids will usually be as a result of the needs of the construction, providing for convenient

restriction sites, ease of manipulation, improvement in levels of expression, or the like. In addition, the substitute of one or more amino acids with a different amino acid can occur for similar reasons, usually not substituting more than about five amino acids in any one domain.

(46) The chimeric construct, which encodes the chimeric receptor according to this invention can be prepared in conventional ways. Since, for the most part, natural sequences are employed, the natural genes are isolated and manipulated, as appropriate (e.g., when employing a Type II receptor, the immune signaling receptor component may have to be inverted), so as to allow for the proper joining of the various components. Thus, the nucleic acid sequences encoding for the N-terminal and C-terminal proteins of the chimeric receptor can be isolated by employing the polymerase chain reaction (PCR), using appropriate primers which result in deletion of the undesired portions of the gene. Alternatively, restriction digests of cloned genes can be used to generate the chimeric construct. In either case, the sequences can be selected to provide for restriction sites which are blunt-ended, or have complementary overlaps.

(47) The various manipulations for preparing the chimeric construct can be carried out in vitro and in particular embodiments the chimeric construct is introduced into vectors for cloning and expression in an appropriate host using standard transformation or transfection methods. Thus, after each manipulation, the resulting construct from joining of the DNA sequences is cloned, the vector isolated, and the sequence screened to insure that the sequence encodes the desired chimeric receptor. The sequence can be screened by restriction analysis, sequencing, or the like.

(48) The chimeric constructs of the present invention find application in subjects having or suspected of having cancer by decreasing FoxP3⁺ T regulatory cells present in the tumor microenvironment and reducing the size of a tumor thereby preventing the growth or regrowth of a tumor in these subjects. Accordingly, the present invention further embraces chimeric NK receptor-bearing T cells and methods for using the same to decrease FoxP3⁺ T regulatory cells present in the tumor microenvironment and reduce growth or prevent tumor formation in a subject.

(49) The methods of this invention involve introducing a chimeric construct of the present invention into an isolated T cell and introducing into a subject the transformed T cell. Suitable T cells which can be used include, cytotoxic lymphocytes (CTL), tumor-infiltrating-lymphocytes (TIL) or other cells which are capable of killing target cells when activated. As is well-known to one of skill in the art, various methods are readily available for isolating these cells from a subject. For example, using cell surface marker expression or using commercially available kits (e.g., ISOCELLTM from Pierce, Rockford, IL). The T cells used in accordance with the invention are, in order of preference, autologous, allogeneic or xenogeneic, and the choice can largely depend on the urgency of the need for treatment. However, in particular embodiments, the T cells are autologous or isolated from the subject being treated.

(50) While the present invention relates to the elimination of tumors, the chimeric NK receptors of the present invention can also be used in the treatment of other diseases where these ligands may be present. For example, the immune response can be down-modulated during autoimmune disease or transplantation by expressing these type of chimeric NK receptors in T regulatory or T suppressor cells. Thus, these cells would mediate their regulatory/suppressive function only in the location where the body has upregulated one of the ligands for these receptors. This ligand upregulation may occur during stress or inflammatory responses.

(51) It is contemplated that the chimeric construct can be introduced into T cells as naked DNA or in a suitable vector. Methods of stably transfecting T cells by electroporation using naked DNA are known in the art. See, e.g., U.S. Pat. No. 6,410,319. Naked DNA generally refers to the DNA encoding a chimeric receptor of the present invention contained in a plasmid expression vector in proper orientation for expression. Advantageously, the use of naked DNA reduces the time required to produce T cells expressing the chimeric receptor of the present invention.

(52) Alternatively, a viral vector (e.g., a retroviral vector, adenoviral vector, adeno-associated viral vector, or lentiviral vector) can be used to introduce the chimeric construct into T cells. Suitable

vectors for use in accordance with the method of the present invention are non-replicating in the T cells. A large number of vectors are known which are based on viruses, where the copy number of the virus maintained in the cell is low enough to maintain the viability of the cell. Illustrative vectors include the pFB-neo vectors (STRATAGENE®) disclosed herein as well as vectors based on HIV, SV40, EBV, HSV or BPV.

(53) Once it is established that the transfected or transduced T cell is capable of expressing the chimeric receptor as a surface membrane protein with the desired regulation and at a desired level, it can be determined whether the chimeric receptor is functional in the host cell to provide for the desired signal induction (e.g., production of Rantes, Mip1-alpha, GM-CSF upon stimulation with the appropriate ligand).

(54) Subsequently, the transduced T cells are introduced or administered to the subject to reduce the regulatory T cell population and activate anti-tumor responses in said subject. To facilitate administration, the transduced T cells according to the invention can be made into a pharmaceutical composition or made implant-appropriate for administration in vivo, with appropriate carriers or diluents, which further can be pharmaceutically acceptable. The means of making such a composition or an implant have been described in the art (see, for instance, Remington's Pharmaceutical Sciences, 16th Ed., Mack, ed. (1980)). Where appropriate, the transduced T cells can be formulated into a preparation in semisolid or liquid form, such as a capsule, solution, injection, inhalant, or aerosol, in the usual ways for their respective route of administration. Means known in the art can be utilized to prevent or minimize release and absorption of the composition until it reaches the target tissue or organ, or to ensure timed-release of the composition. Desirably, however, a pharmaceutically acceptable form is employed which does not ineffectuate the cells expressing the chimeric receptor. Thus, desirably the transduced T cells can be made into a pharmaceutical composition containing a balanced salt solution, preferably Hanks' balanced salt solution, or normal saline.

(55) A pharmaceutical composition of the present invention can be used alone or in combination with other well-established agents useful for treating cancer. Whether delivered alone or in combination with other agents, the pharmaceutical composition of the present invention can be delivered via various routes and to various sites in a mammalian, particularly human, body to achieve a particular effect. One skilled in the art will recognize that, although more than one route can be used for administration, a particular route can provide a more immediate and more effective reaction than another route. For example, intradermal delivery may be advantageously used over inhalation for the treatment of melanoma. Local or systemic delivery can be accomplished by administration comprising application or instillation of the formulation into body cavities, inhalation or insufflation of an aerosol, or by parenteral introduction, comprising intramuscular, intravenous, intraportal, intrahepatic, peritoneal, subcutaneous, or intradermal administration.

(56) A composition of the present invention can be provided in unit dosage form wherein each dosage unit, e.g., an injection, contains a predetermined amount of the composition, alone or in appropriate combination with other active agents. The term unit dosage form as used herein refers to physically discrete units suitable as unitary dosages for human and animal subjects, each unit containing a predetermined quantity of the composition of the present invention, alone or in combination with other active agents, calculated in an amount sufficient to produce the desired effect, in association with a pharmaceutically acceptable diluent, carrier, or vehicle, where appropriate. The specifications for the novel unit dosage forms of the present invention depend on the particular pharmacodynamics associated with the pharmaceutical composition in the particular subject.

(57) Desirably an effective amount or sufficient number of the isolated transduced T cells is present in the composition and introduced into the subject such that long-term, specific, anti-tumor responses are established to reduce the size of a tumor or eliminate tumor growth or regrowth than would otherwise result in the absence of such treatment. Desirably, the amount of transduced T

cells introduced into the subject causes a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, or 100% decrease in tumor size when compared to otherwise same conditions wherein the transduced T cells are not present.

(58) In embodiments drawn to an elimination or decrease in the regulatory T cell population of a subject, it is desired that the transduced T cells introduced into the subject cause a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, or 100% decrease in the number of FoxP3⁺ T regulatory cells in the subject being treated as compared to a subject not receiving such treatment. In particular embodiments, the transduced T cells are administered to a subject having or suspected of having cancer so that the population of regulatory T cells is decreased at or near a tumor. A decrease in regulatory T cell population can be determined by, e.g., FACS analysis of a cell sample, wherein cells are sorted based upon the presence of cell surface markers. For example, regulatory T cells can be sorted and counted based upon the presence of CD4, CD25, and Fox3P.

(59) The amount of transduced T cells administered should take into account the route of administration and should be such that a sufficient number of the transduced T cells will be introduced so as to achieve the desired therapeutic response. Furthermore, the amounts of each active agent included in the compositions described herein (e.g., the amount per each cell to be contacted or the amount per certain body weight) can vary in different applications. In general, the concentration of transduced T cells desirably should be sufficient to provide in the subject being treated at least from about 1×10^{10} to about 1×10^{12} transduced T cells, even more desirably, from about 1×10^{11} to about 5×10^{12} transduced T cells, although any suitable amount can be utilized either above, e.g., greater than 5×10^{12} cells, or below, e.g., less than 1×10^{11} cells. The dosing schedule can be based on well-established cell-based therapies (see, e.g., Topalian and Rosenberg (1987) *Acta Haematol.* 78 Suppl 1:75-6; U.S. Pat. No. 4,690,915) or an alternate continuous infusion strategy can be employed.

(60) These values provide general guidance of the range of transduced T cells to be utilized by the practitioner upon optimizing the methods of the present invention for practice of the invention. The recitation herein of such ranges by no means precludes the use of a higher or lower amount of a component, as might be warranted in a particular application. For example, the actual dose and schedule can vary depending on whether the compositions are administered in combination with other pharmaceutical compositions, or depending on interindividual differences in pharmacokinetics, drug disposition, and metabolism. One skilled in the art readily can make any necessary adjustments in accordance with the exigencies of the particular situation.

(61) In particular embodiments, the chimeric nucleic acid construct further contains a suicide gene such as thymidine kinase (TK) of the HSV virus (herpesvirus) type I (Bonini, et al. (1997) *Science* 276:1719-1724), a Fas-based “artificial suicide gene” (Thomis, et al. (2001) *Blood* 97:1249-1257), or *E. coli* cytosine deaminase gene which are activated by gancyclovir, AP1903, or 5-fluorocytosine, respectively. The suicide gene is advantageously included in the nucleic acid construct of the present invention to provide for the opportunity to ablate the transduced T cells in case of toxicity and to destroy the chimeric construct once a tumor has been reduced or eliminated. The use of suicide genes for eliminating transformed or transduced cells is well-known in the art. For example, Bonini, et al. ((1997) *Science* 276:1719-1724) teach that donor lymphocytes transduced with the HSV-TK suicide gene provide antitumor activity in patients for up to one year and elimination of the transduced cells is achieved using ganciclovir. Further, Gonzalez, et al. ((2004) *J. Gene Med.* 6:704-711) describe the targeting of neuroblastoma with cytotoxic T lymphocyte clones genetically modified to express a chimeric scFvFc: ζ immunoreceptor specific for an epitope on L1-CAM, wherein the construct further expresses the hygromycin thymidine kinase (HyTK) suicide gene to eliminate the transgenic clones.

(62) It is contemplated that the suicide gene can be expressed from the same promoter as the chimeric receptor or from a different promoter. Generally, however, nucleic acid sequences encoding the suicide protein and chimeric receptor reside on the same construct or vector.

Expression of the suicide gene from the same promoter as the chimeric receptor can be accomplished using any well-known internal ribosome entry site (IRES). Suitable IRES sequences which can be used in the nucleic acid construct of the present invention include, but are not limited to, IRES from EMCV, c-myc, FGF-2, poliovirus and HTLV-1. By way of illustration, a nucleic acid construct for expressing a chimeric receptor can have the following structure:

promoter.fwdarw.chimeric receptor.fwdarw.IRES.fwdarw.suicidal gene. Alternatively, the suicide gene can be expressed from a different promoter than that of the chimeric receptor (e.g., promoter 1.fwdarw.chimeric receptor.fwdarw.promoter 2.fwdarw.suicidal gene).

(63) The following non-limiting examples are presented to better illustrate the invention.

Example 1: Mice and Cell Lines

(64) C57BL/6 mice were purchased from the National Cancer Institute, and all animal work was conducted in accordance with standard guidelines.

(65) Cell lines Bosc23, PT67, GP+E86, EG7 (H-2.sup.b), and YAC-1 were obtained from the American Type Culture Collection (ATCC, Rockville, MD). RMA cells (H-2.sup.b) originated from a Rauscher virus-induced C57BL/6 T-cell lymphoma (Ljunggren and Karre (1985) *J. Exp. Med.* 162:1745-1759). RMA-S is a sub-line of RMA which lacks MHC class-I surface expression (Karre, et al. (1986) *Nature* 319:675-678). All packaging cells were grown in Dulbecco's modified Eagle medium (DMEM) with a high glucose concentration (4.5 gram/liter) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Hyclone, Logan, UT), 20 U/mL penicillin, 20 µg/mL streptomycin, 1 mM pyruvate, 10 mM HEPES, 0.1 mM non-essential amino acids, 50 µM 2-mercaptoethanol. RMA, EG7, RMA-S and YAC-1 cells were cultured in RPMI plus the same supplements described above.

Example 2: Retroviral Vector Construction

(66) The full-length murine NKG2D cDNA was purchased from Open Biosystems (Huntsville, AL). Murine CD3ζ chain, Dap10 and Dap12 cDNAs were cloned by RT-PCR using RNAs from ConA- or IL-2 (1000 U/mL)-activated spleen cells as templates. Mouse NKG2D ligands Rae-1β and H60 were cloned from YAC-1 cells by RT-PCR. All PCR reactions were performed using high-fidelity enzyme Pfu or PFUULTRA™ (STRATAGENE®, La Jolla, CA). The oligonucleotides employed in these PCR reactions are listed in Table 9.

(67) TABLE-US-00009

TABLE	9	SEQ ID No.	Primer Sequence NO:
<u>GCGAATTCGCCACCATGGCATTGATTCGTGATCGA</u>	8	2	3' wtNKG2D
<u>GGCGCTCGAGTTACACCGCCCTTTTCATGCAGAT</u>	9	3	5' chNKG2D
<u>GGCGAATTCGCATTGATTCGTGATCGAAAGTCT</u>	10	4	5' wtDAP10
<u>GCAAGTCGACGCCACCATGGACCCCCCAGGCTACC</u>	11	5	3' wtDAP10
<u>GGCGAATTCCTCAGCCTCTGCCAGGCATGTTGAT</u>	12	6	3' chDAP10
<u>GGCAGAATTCGCCTCTGCCAGGCATGTTGATGTA</u>	13	7	5' wtDAP12
<u>GTTAGAATTCGCCACCATGGGGGCTCTGGAGCCCT</u>	14	8	3' wtDAP12
<u>GCAACTCGAGTCATCTGTAATATTGCCTCTGTG</u>	15	9	5' ATG-CD3ζ
<u>GGCGTCGACACCATGAGAGCAAAATTCAGCAGGAG</u>	16	10	3' ATG-CD3ζ
<u>GCTTGAATTCGCGAGGGGCCAGGGTCTGCATAT</u>	17	11	5' CD3ζ-TAA
<u>GCAGAATTCAGAGCAAAATTCAGCAGGAGTGC</u>	18	12	3' CD3ζ-TAA
<u>GCTTTCTCGAGTTAGCGAGGGGCCAGGGTCTGCAT</u>	19	13	5' Rae-1
<u>GCATGTCGACGCCACCATGGCCAAGGCAGCAGTGA</u>	20	14	3' Rae-1
<u>GCGGCTCGAGTCACATCGCAAATGCAAATGC</u>	21	15	5' H60
<u>GTTAGAATTCGCCACCATGGCAAAGGGAGCCACC</u>	22	16	3' H60
<u>GCGCTCGAGTCATTTTTTCTTCAGCATAACCAAG</u>	23		Restriction sites inserted for cloning purposes are underlined.

(68) Chimeric NKG2D was created by fusing the murine CD3 chain cytoplasmic region coding sequence (CD3ζ-CYP) to the full-length gene of murine NKG2D. Briefly, the Sa1I-EcoRI fragment of CD3ζ-CYP (with the initiation codon ATG at the 5' end, primer numbers 9 and 10) and the

EcoRI-XhoI fragment of NKG2D (without ATG, primer numbers 2 and 3) were ligated into the SalI/XhoI-digested pFB-neo retroviral vector (STRATAGENE®, La Jolla, CA). Similarly, chimeric Dap10 was generated by fusing the SalI-EcoRI fragment of full-length Dap10 (primer numbers 4 and 6) to the EcoRI-XhoI fragment of CD3ζ-CYP (primer numbers 11 and 12). Wild-type NKG2D (primer numbers 2 and 3), Dap10 (primer numbers 4 and 5) and Dap12 (primer numbers 7 and 8) fragments were inserted between the EcoRI and XhoI sites in pFB-neo. In some cases, a modified vector pFB-IRES-GFP was used to allow co-expression of green fluorescent protein (GFP) with genes of interest. pFB-IRES-GFP was constructed by replacing the 3.9 kb AvrUScaI fragment of pFB-neo with the 3.6 kb AvrII/ScaI fragment of a plasmid GFP-RV(Ouyang, et al. (1998) *Immunity* 9:745-755). Rae-1β (primer numbers 13 and 14) and H60 (primer numbers 15 and 16) cDNAs were cloned into pFB-neo. Constructs containing human NKD2D and human CD3ζ or murine Fc were prepared in the same manner using the appropriate cDNAs as templates.

Example 3: Retrovirus Production and Transduction

(69) Eighteen hours before transfection, Bosc23 cells were plated in 25 cm.sup.2 flasks at a density of 4×10.sup.6 cells per flask in 6 mL of DMEM-10. Transfection of retroviral constructs into Bosc23 cells was performed using LIPOFECTAMINE™ 2000 (INVITROGEN™, Carlsbad, CA) according to the manufacturer's instruction. Viral supernatants were collected 48 and 72 hours post-transfection and filtered (0.45 μm) before use. For generation of large scale, high-titer ecotropic vectors, the ecotropic viruses produced above were used to transduce the dualtropic packaging cell PT67 in the presence of polybrene (8 μg/mL). After three rounds of transduction, PT67 cells were selected in 6418 (1 mg/mL) for 7 days. Dualtropic vectors were then used to transduce ecotropic cell line GP+E86. Through this process, the virus titer from pooled GP+E86 cells generally was over 1×10.sup.6 CFU/mL. Concentration of retroviruses by polyethylene glycol (PEG) was performed according to standard methods (Zhang, et al. (2004) *Cancer Gene Ther.* 11:487-496; Zhang, et al. (2003) *J. Hametother. Stem Cell Res.* 12:123-130). Viral stocks with high titer (1-2×10.sup.7 CFU/mL) were used for transduction of T cells. Primary T cells from spleens of C57BL/6 (B6) mice were infected 18-24 hours after concanavalin A (ConA, 1 μg/mL) stimulation based on a well-established protocol (Sentman, et al. (1994) *J. Immunol.* 153:5482-5490). Two days after infection, transduced primary T cells (0.5-1×10.sup.6/mL) were selected in RPMI-10 media containing G418 (0.5 mg/mL) plus 25 U/mL rHuIL-2 for an additional 3 days. Viable cells were isolated using HISTOPAQUE®-1083 (Sigma, St. Louise, MO) and expanded for 2 days without G418 before functional analyses. NKG2D ligand-expressing RMA (RMA/Rae-1β and RMA/H60) or RMA-S (RMA-S/Rae-1β) cells were established by retroviral transduction with dualtropic vectors from PT67.

Example 4: Cytokine Production by Gene-Modified T Cells

(70) Gene-modified primary T cells (10.sup.5) were co-cultured with an equal number of RMA, RMA/Rae-1β, RMA/H60 or YAC-1 cells in 96-well plates in complete media. After twenty-four hours, cell-free supernatants were collected. IFN-γ was assayed by ELISA using a DUOSET® ELISA kits (R&D, Minneapolis, MN). In some cases, T cells were cultured with equal numbers of irradiated (100 Gys) tumor cells for 3 days. Detection of other cytokines in culture was performed using a BIO-PLEX® kit (BIO-RAD®, Hercules, CA) based on the manufacturer's protocol.

Example 5: Flow Cytometry

(71) For FACS analysis of NKG2D ligand expression, tumor cells were stained with mouse NKG2D-Ig fusion protein (R&D systems) according to manufacturer's instruction. Cell-surface phenotyping of transduced primary T cells was determined by direct staining with APC-anti-CD3ε (clone 145-2C11; Pharmingen, San Diego, CA), PE-anti-NKG2D (clone 16-10A1; eBioscience, San Diego, CA) and FITC-anti-CD4 (Clone RM4-5; Caltag, Burlingame, CA) monoclonal antibodies. Cell fluorescence was monitored using a FACSCALIBER™ cytometer. Sorting of NKG2D ligand-expressing cells was performed on a FACSTARM™ cell sorter (Becton Dickinson, San Jose, CA).

Example 6: Cytotoxicity Assay

(72) Three or four days after G418 selection (0.5 mg/mL), retroviral vector-transduced primary T cells were cultured in complete RPMI media containing 25 U/mL human IL-2 for an additional 2-3 days. Viable lymphocytes were recovered by centrifugation over HISTOPAQUE®-1083 (Sigma, St. Louis, MO) and used as effector cells. Lysis of target cells (RMA, RMA/Rae-1 β , RMA/H60, EG7, RMA-S, RMA-S/Rae-1 β , and YAC-1) was determined by a 4-hour .sup.51Cr release assay (Sentman, et al. (1994) supra). To block NKG2D receptors, anti-NKG2D (clone: CX5, 20 μ g/mL) was included in those assays. The percentage of specific lysis was calculated as follows:

(73) % Specific lysis=[(Specific .sup.51Cr release–spontaneous .sup.51Cr release)/(Maximal .sup.51Cr release–spontaneous .sup.51Cr release)] \times 100.

Example 7: Treatment of Mice with Genetically Modified T Cells

(74) For the determination of direct effects of chimeric NKG2D-bearing T cells (10.sup.6) on the growth of RMA or RMA/Rae-1 β tumors, chimeric NKG2D- or vector-transduced T cells were mixed with tumor cells (10.sup.5) and then injected s.c. into the shaved right flank of recipient mice. Tumors were then measured using a caliper, and tumor areas were calculated. Animals were regarded as tumor-free when no tumor was found four weeks after inoculation. For the rechallenge experiments, mice were inoculated with 10.sup.4 RMA cells on the shaved left flank. In other experiments, transduced T cells were injected intravenously the day before s.c. inoculation of tumor cells. Mice were monitored for tumor size every two days and were sacrificed when tumor burden became excessive.

Example 8: Statistical Analysis

(75) Differences between groups were analyzed using the student's t-test. p values<0.05 were considered significant.

Claims

1. A method for obtaining human T-lymphocytes (human T cells) for potential use in immunotherapy comprising (i) introducing into an isolated human T cell at least one nucleic acid construct comprising: a first nucleic acid sequence encoding a promoter operably linked to a second nucleic acid sequence encoding a chimeric receptor polypeptide, said second nucleic acid sequence comprising a nucleic acid encoding a C-type lectin-like type II natural killer cell receptor polypeptide fused to a nucleic acid encoding an immune signaling receptor polypeptide comprising SEQ ID NO:1, wherein said C-type lectin type II natural killer receptor polypeptide binds a ligand and activates an immune signaling receptor polypeptide comprising SEQ ID NO: 1, (ii) optionally expanding said human T cells which comprise said at least one nucleic acid construct; and (ii) isolating human T cells which express said chimeric receptor polypeptide on their surface.
2. The method of claim 1, wherein the construct is in a vector.
3. The method of claim 1, wherein the construct further comprises a suicide gene.
4. The method of claim 1, wherein the C-type lectin-like NK cell type II receptor is at the C-terminus of the chimeric receptor polypeptide and the immune signaling receptor polypeptide is at the N-terminus of the chimeric receptor polypeptide.
5. The method of claim 1, wherein the C-type lectin-like NK cell type II receptor is human NKG2D having the sequence set forth in SEQ ID NO:2 or is human NKG2C having the sequence set forth in SEQ ID NO:3.
6. The method of claim 1, wherein the immune signaling receptor is CD3-zeta having the sequence set forth in SEQ ID NO:6, or is human Fc epsilon receptor-gamma chain having the sequence set forth in SEQ ID NO:7 or the cytoplasmic domain or a splicing variant thereof.
7. The method of claim 1, wherein the chimeric receptor polypeptide is a fusion between NKG2D and CD3-zeta.
8. The method of claim 1, wherein the C-type lectin-like NK cell type II receptor is human

NKG2D.

9. The method of claim 8, wherein the nucleic acid construct further comprises a nucleic acid encoding DAP10 or DAP12.

10. The method of claim 1, wherein the T cells comprise primary human T cells.

11. The method of claim 8, wherein the T cells comprise primary human T cells.

12. The method of claim 1, wherein said T cells comprise T regulatory cells.

13. The method of claim 1, wherein said T cells comprise T suppressor cells.

14. The method of claim 1, wherein said T cells comprise CD8.sup.+ T cells.

15. The method of claim 8, wherein said T cells comprise CD8.sup.+ T cells.

16. The method of claim 1, wherein the C-type lectin-like NK cell type II receptor is selected from Dectin-1, Mast cell function-associated antigen, HNKRP-1A, LLT1, CD69, CD69 homolog, CD72, CD94, KLRF1, Oxidized LDL receptor, CLEC-1, CLEC-2, NKG2D, NKG2C, NKG2A, NKG2E, and Myeloid DAP12-associating lectin.
